Interestingly, neuronal-enriched systemic EVs (phosphorylated tau, amyloid β42 (Aβ42) and phosphorylated insulin receptor substrate 1 (IRS-1)) were recently reported as validated biomarkers for Alzheimer’s disease (AD) [110]. This evidence concerns the gene MAPT and Alzheimer disease.